Federal Courts to Hear Challenges to DEA's Schedule III Cannabis Rule

Petitions Challenge Administrative Procedure and CSA Criteria

Four separate petitions for review were filed in federal circuit courts between July 8 and July 29, 2026, each asserting the DEA violated the Administrative Procedure Act or misapplied the Controlled Substances Act's eight-factor test. The petitioners include a coalition of anti-legalization advocacy groups, two state attorneys general, one Schedule I research permit holder, and a coalition of hemp industry trade associations. All four cases were consolidated by the Judicial Panel on Multidistrict Litigation and assigned to the U.S. Court of Appeals for the District of Columbia Circuit on July 31, 2026.

Petitioners argue the DEA failed to respond adequately to over 43,000 public comments submitted during the notice-and-comment period that closed March 22, 2026. The APA requires meaningful engagement. The final rule's preamble addressed comments in 127 pages, but petitioners say the agency provided only cursory responses to substantive objections regarding abuse potential, international treaty obligations, and the absence of FDA-approved cannabis formulations.

The CSA requires the Attorney General—acting through the DEA—to consider eight factors when scheduling a drug: actual or relative potential for abuse, scientific evidence of pharmacological effect, and whether the substance has a currently accepted medical use in treatment in the United States, among others. Petitioners contend the DEA's findings on factors three, four, and six are arbitrary and capricious.

Tax Implications Hinge on Final Judicial Outcome

If courts vacate the Schedule III rule, cannabis businesses will revert to full IRC §280E disallowance of ordinary and necessary business expenses, eliminating the cost-of-goods-sold deduction that became available June 1, 2026. Multi-state operators reported in second-quarter 2026 earnings calls that the Schedule III effective date reduced effective federal tax rates from an average of 70 percent of gross profit to approximately 28 percent of net income. A judicial reversal would reinstate the prior tax treatment retroactively or prospectively depending on the remedy ordered by the court.

Treasury hasn't issued formal guidance on how taxpayers should treat expenses deducted between June 1 and any potential vacatur date. Practitioners note that if the court vacates the rule with retroactive effect, taxpayers who filed 2026 returns claiming COGS and ordinary deductions may face amended return requirements and underpayment penalties. If vacatur is prospective only, the tax treatment for the interim period would likely stand, but operators would lose the deduction going forward.

Standing and Ripeness Questions May Narrow the Field

The government is expected to move to dismiss at least two of the four petitions on standing grounds, arguing that the hemp trade associations and the research permit holder haven't suffered injury in fact from the rescheduling. The hemp petitioners claim Schedule III status for cannabis blurs the regulatory line between hemp (defined as cannabis with ≤0.3% delta-9 THC under the 2018 Farm Bill) and marijuana. Market confusion follows. Potential enforcement overreach, too. The research petitioner, a university holding a DEA Schedule I research registration, asserts the rescheduling eliminates the regulatory justification for its research program and threatens future grant funding.

DOJ's anticipated standing argument will rely on the Supreme Court's decision in Lujan v. Defenders of Wildlife, which requires plaintiffs to show concrete and particularized injury that's actual or imminent, fairly traceable to the challenged action, and likely to be redressed by a favorable decision. The hemp associations' injury theory is attenuated; the research petitioner's injury is speculative absent evidence that grant funding has been withdrawn or denied.

Abuse Potential Findings Under Scrutiny

Petitioners assert the DEA's finding that cannabis has lower abuse potential than Schedule II substances contradicts the agency's own prior determinations and peer-reviewed literature on cannabis use disorder. The final rule states that cannabis meets the criteria for Schedule III because it has a potential for abuse less than Schedule I and II substances and has a currently accepted medical use. The rule cites FDA's conclusion that cannabis has accepted medical use based on state programs operating under the 2018 Farm Bill's research provisions and compassionate use frameworks in 38 states as of May 2026.

Critics point to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, which recognizes cannabis use disorder as a clinical diagnosis, and to National Survey on Drug Use and Health data showing approximately 16.3 million Americans met criteria for cannabis use disorder in 2025. In the final rule, the DEA responds that abuse potential is assessed relative to other controlled substances, not in absolute terms, and that the eight-factor analysis supports a Schedule III placement when all factors are weighed together.

International Treaty Obligations and Single Convention Compliance

The United States is a party to the 1961 Single Convention on Narcotic Drugs, which lists cannabis and cannabis resin in Schedule I and Schedule IV of that treaty. Petitioners argue that domestic rescheduling to CSA Schedule III places the U.S. in breach of its treaty obligations. Schedule I under the Single Convention requires the highest level of control. The DEA's final rule addresses this argument by noting that the Single Convention doesn't mandate specific domestic scheduling; it requires only that parties adopt measures to limit the use of scheduled substances to medical and scientific purposes.

State Department officials submitted comments during the NPRM period stating that rescheduling to Schedule III wouldn't violate the Single Convention if the U.S. maintains adequate controls to prevent diversion and limits use to medical purposes. The DEA adopted this position in the final rule. Petitioners counter that the rule's preamble provides no analysis of how state-licensed adult-use programs—operating in 24 states as of June 2026—can be reconciled with the medical-use limitation, and that the agency's silence on this point renders the rule arbitrary.

Briefing Schedule and Oral Argument Timeline

The D.C. Circuit issued a briefing schedule on August 1, 2026, requiring petitioners' opening briefs by September 15, 2026, the government's response by October 30, 2026, and reply briefs by November 20, 2026. Oral argument is tentatively set for the week of January 12, 2027. The court designated the case as expedited due to the immediate operational and financial impact on regulated entities. A decision is expected in the second quarter of 2027.

If the court rules for petitioners and vacates the rule, the DEA would be required to re-initiate rulemaking or return cannabis to Schedule I pending a new administrative process. If the court upholds the rule, petitioners may seek en banc review or petition the Supreme Court for certiorari, though the likelihood of further review depends on whether the D.C. Circuit's decision creates a circuit split or addresses a question of exceptional importance.

What Operators and Tax Advisors Should Watch

Cannabis operators should model tax scenarios under both Schedule III and Schedule I assumptions for fiscal years 2026 and 2027, and consider reserving cash for potential amended return liabilities. The prudent course for operators filing 2026 returns before a final judicial decision is to claim the Schedule III treatment but disclose the pending litigation in footnotes and maintain adequate reserves for the possibility of retroactive disallowance. Tax advisors are counseling clients to avoid aggressive positions on the scope of COGS or the character of deductible expenses until the litigation resolves.

For comprehensive background on the rescheduling process and the regulatory history leading to the May 2026 final rule, see the CannIntel topic hub on Schedule III rescheduling. The next major inflection point will be the government's response brief due October 30, 2026, which will clarify DOJ's defense strategy and may preview settlement discussions if the administration seeks to moot the litigation through further rulemaking.